In both ovarian and breast cancer PARP inhibitor-resistant xenograft models, mice treated with the combination of PARP and ALK inhibitors demonstrated improved survival compared with mice treated with monotherapy (Fig. 6a–d, right panels). This evidence concerns the gene PARP1 and breast cancer.